The kinase inhibitors sunitinib and sorafenib differentially affect NK cell antitumor reactivity in vitro

Journal of Immunology

Volumn 183, Issue 12, 2009, Pages 8286-8294

  Krusch, Matthias ^a   Salih, Julia ^a   Schlicke, Manuela ^a   Baessler, Tina ^a   Kampa, Kerstin Maria ^a   Mayer, Frank ^a   Salih, Helmut Rainer ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 2; MITOGEN ACTIVATED PROTEIN KINASE; SORAFENIB; SUNITINIB; ANTINEOPLASTIC AGENT; BENZENESULFONIC ACID DERIVATIVE; INDOLE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIDINE DERIVATIVE; PYRROLE DERIVATIVE;

ADAPTIVE IMMUNITY; ADVANCED CANCER; ARTICLE; CANCER REGRESSION; CANCER THERAPY; CHEMOREACTIVITY; CYTOKINE PRODUCTION; CYTOTOXICITY; EFFECTOR CELL; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IN VITRO STUDY; KIDNEY CANCER; NATURAL KILLER CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; TARGET CELL; TUMOR IMMUNITY; ANIMAL; CELL CULTURE; CELL LINE; CELL STRAIN K 562; COCULTURE; COMPARATIVE STUDY; DOSE RESPONSE; DRUG COMBINATION; DRUG EFFECT; DRUG POTENTIATION; IMMUNOLOGY; MOUSE; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CELL LINE; CELL LINE, TUMOR; CELLS, CULTURED; COCULTURE TECHNIQUES; CYTOTOXICITY, IMMUNOLOGIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; HUMANS; INDOLES; K562 CELLS; KILLER CELLS, NATURAL; MICE; PROTEIN KINASE INHIBITORS; PYRIDINES; PYRROLES; SIGNAL TRANSDUCTION;

EID: 76249129410     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0902404     Document Type: Article

References (44)

1. Motzer, R. J., and R. M. Bukowski. 2006. Targeted therapy for metastatic renal cell carcinoma. J. Clin. Oncol. 24: 5601-5608. (Pubitemid 46631341)
2. Iliopoulos, O. 2006. Molecular biology of renal cell cancer and the identification of therapeutic targets. J. Clin. Oncol. 24: 5593-5600. (Pubitemid 46631340)
3. Goodman, V. L., E. P. Rock, R. Dagher, R. P. Ramchandani, S. Abraham, J. V. Gobburu, B. P. Booth, S. L. Verbois, D. E. Morse, C. Y. Liang, et al. 2007. Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma. Clin. Cancer Res. 13: 1367-1373.
4. Motzer, R. J., T. E. Hutson, P. Tomczak, M. D. Michaelson, R. M. Bukowski, O. Rixe, S. Oudard, S. Negrier, C. Szczylik, S. T. Kim, et al. 2007. Sunitinib versus interferon α in metastatic renal-cell carcinoma. N. Engl. J. Med. 356: 115-124.
5. Kane, R. C., A. T. Farrell, H. Saber, S. Tang, G. Williams, J. M. Jee, C. Liang, B. Booth, N. Chidambaram, D. Morse, et al. 2006. Sorafenib for the treatment of advanced renal cell carcinoma. Clin. Cancer Res. 12: 7271-7278.
6. Escudier, B., T. Eisen, W. M. Stadler, C. Szczylik, S. Oudard, M. Siebels, S. Negrier, C. Chevreau, E. Solska, A. A. Desai, et al. 2007. Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med. 356: 125-134.
7. Yang, J. C., and R. Childs. 2006. Immunotherapy for renal cell cancer. J. Clin. Oncol. 24: 5576-5583.
8. Parton, M., M. Gore, and T. Eisen. 2006. Role of cytokine therapy in 2006 and beyond for metastatic renal cell cancer. J. Clin. Oncol. 24: 5584-5592.
9. Trinchieri, G., M. Matsumoto-Kobayashi, S. C. Clark, J. Seehra, L. London, and B. Perussia. 1984. Response of resting human peripheral blood natural killer cells to interleukin 2. J. Exp. Med. 160: 1147-1169.
10. Vivier, E., E. Tomasello, M. Baratin, T. Walzer, and S. Ugolini. 2008. Functions of natural killer cells. Nat. Immunol. 9: 503-510.
11. Lanier, L. L. 2005. NK cell recognition. Annu. Rev. Immunol. 23: 225-274.
12. Dunn, G. P., L. J. Old, and R. D. Schreiber. 2004. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 21: 137-148.
13. Walzer, T., M. Dalod, S. H. Robbins, L. Zitvogel, and E. Vivier. 2005. Naturalkiller cells and dendritic cells: "l'union fait la force". Blood 106: 2252-2258.
14. Cooper, M. A., T. A. Fehniger, A. Fuchs, M. Colonna, and M. A. Caligiuri. 2004. NK cell and DC interactions. Trends Immunol. 25: 47-52.
15. Ljunggren, H. G., and K. J. Malmberg. 2007. Prospects for the use of NK cells in immunotherapy of human cancer. Nat. Rev. Immunol. 7: 329-339. (Pubitemid 46674487)
16. Fabian, M. A., W. H. Biggs, III, D. K. Treiber, C. E. Atteridge, M. D. Azimioara, M. G. Benedetti, T. A. Carter, P. Ciceri, P. T. Edeen, M. Floyd, et al. 2005. A small molecule-kinase interaction map for clinical kinase inhibitors. Nat. Biotechnol. 23: 329-336.
17. Faivre, S., C. Delbaldo, K. Vera, C. Robert, S. Lozahic, N. Lassau, C. Bello, S. Deprimo, N. Brega, G. Massimini, et al. 2006. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J. Clin. Oncol. 24: 25-35.
18. Clark, J. W., J. P. Eder, D. Ryan, C. Lathia, and H. J. Lenz. 2005. Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors. Clin. Cancer Res. 11: 5472-5480.
19. Yee, K. W., M. Schittenhelm, A. M. O'farrell, A. R. Town, L. McGreevey, T. Bainbridge, J. M. Cherrington, and M. C. Heinrich. 2004. Synergistic effect of SU11248 with cytarabine or daunorubicin on FLT3 ITD-positive leukemic cells. Blood 104: 4202-4209.
20. Baltz, K. M., M. Krusch, A. Bringmann, P. Brossart, F. Mayer, M. Kloss, T. Baessler, I. Kumbier, A. Peterfi, S. Kupka, et al. 2007. Cancer immunoediting by GITR (glucocorticoid-induced TNF-related protein) ligand in humans: NK cell/tumor cell interactions. FASEB J. 21: 2442-2454.
21. Jiang, K., B. Zhong, D. L. Gilvary, B. C. Corliss, E. Hong-Geller, S. Wei, and J. Y. Djeu. 2000. Pivotal role of phosphoinositide-3 kinase in regulation of cytotoxicity in natural killer cells. Nat. Immunol. 1: 419-425.
22. Alter, G., J. M. Malenfant, and M. Altfeld. 2004. CD107a as a functional marker for the identification of natural killer cell activity. J. Immunol. Methods 294: 15-22. (Pubitemid 39626587)
23. Lanier, L. L. 2008. Up on the tightrope: natural killer cell activation and inhibition. Nat. Immunol. 9: 495-502. (Pubitemid 351560518)
24. Djeu, J. Y., K. Jiang, and S. Wei. 2002. A view to a kill: signals triggering cytotoxicity. Clin. Cancer Res. 8: 636-640.
25. Mainiero, F., A. Gismondi, A. Soriani, M. Cippitelli, G. Palmieri, J. Jacobelli, M. Piccoli, L. Frati, and A. Santoni. 1998. Integrin-mediated ras-extracellular regulated kinase (ERK) signaling regulates interferon γ production in human natural killer cells. J. Exp. Med. 188: 1267-1275.
26. Wei, S., A. M. Gamero, J. H. Liu, A. A. Daulton, N. I. Valkov, J. A. Trapani, A. C. Larner, M. J. Weber, and J. Y. Djeu. 1998. Control of lytic function by mitogen-activated protein kinase/extracellular regulatory kinase 2 (ERK2) in a human natural killer cell line: identification of perforin and granzyme B mobilization by functional ERK2. J. Exp. Med. 187: 1753-1765. (Pubitemid 28262440)
27. Appel, S., S. Balabanov, T. H. Brummendorf, and P. Brossart. 2005. Effects of imatinib on normal hematopoiesis and immune activation. Stem Cells 23: 1082-1088. (Pubitemid 41377724)
28. + T lymphocytes through inhibition of T cell receptor signalling. J. Cell Mol. Med. 12: 2107-2118.
29. Schade, A. E., G. L. Schieven, R. Townsend, A. M. Jankowska, V. Susulic, R. Zhang, H. Szpurka, and J. P. Maciejewski. 2008. Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation. Blood 111: 1366-1377.
30. Blake, S. J., L. A. Bruce, C. K. Fraser, J. D. Hayball, and T. P. Hughes. 2008. Dasatinib suppresses in vitro natural killer cell cytotoxicity. Blood 111: 4415-4416.
31. + T-cell responses and NK-cell cytolytic activity in vitro and in vivo. Exp. Hematol. 37: 256-265.
32. Caligiuri, M. A. 2008. Human natural killer cells. Blood 112: 461-469.
33. Imai, K., S. Matsuyama, S. Miyake, K. Suga, and K. Nakachi. 2000. Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population. Lancet 356: 1795-1799.
34. Colonna, M., H. Nakajima, and M. Cella. 1999. Inhibitory and activating receptors involved in immune surveillance by human NK and myeloid cells. J. Leukocyte Biol. 66: 718-722. (Pubitemid 29532029)
35. Young, H. A., and J. Ortaldo. 2006. Cytokines as critical co-stimulatory molecules in modulating the immune response of natural killer cells. Cell Res. 16: 20-24. (Pubitemid 43129305)
36. Yokoyama, W. M., and B. F. Plougastel. 2003. Immune functions encoded by the natural killer gene complex. Nat. Rev. Immunol. 3: 304-316.
37. Upshaw, J. L., L. N. Arneson, R. A. Schoon, C. J. Dick, D. D. Billadeau, and P. J. Leison. 2006. NKG2D-mediated signaling requires a DAP10-bound Grb2-Vav1 intermediate ad phosphatidylinositol-3-kinase in human natural killer cells. Nat. Immunol. 7: 524-532.
38. Chuang, S. S., P. R. Kumaresan, and P. A. Mathew. 2001. 2B4 (CD244)-mediated activation of cytotoxicity and IFN-γ release in human NK cells involves distinct pathways. J. Immunol. 167: 6210-6216.
39. Yu, T. K., E. G. Caudell, C. Smid, and E. A. Grimm. 2000. IL-2 activation of NK cells: involvement of MKK1/2/ERK but not p38 kinase pathway. J. Immunol. 164: 6244-6251.
40. Mavropoulos, A., G. Sully, A. P. Cope, and A. R. Clark. 2005. Stabilization of IFN-γ mRNA by MAPK p38 in IL-12- and IL-18-stimulated human NK cells. Blood 105: 282-288.
41. Lieberman, L. A., and C. A. Hunter. 2002. Regulatory pathways involved in the infection-induced production of IFN-γ by NK cells. Microbes Infect. 4: 1531-1538.
42. Hipp, M. M., N. Hilf, S. Walter, D. Werth, K. M. Brauer, M. P. Radsak, T. Weinschenk, H. Singh-Jasuja, and P. Brossart. 2008. Sorafenib but not sunitinib affects function of dendritic cells and induction of primary immune responses. Blood 111: 5610-5620.
43. Szczylik, C., T. Demkow, M. Staehler, F. Rolland, S. Negrier, T. E. Hutson, R. M. Bukowski, U. J. Scheuring, K. Burk, and B. Escudier. 2007. Randomized phase II trial of first-line treatment with sorafenib versus interferon in patients with advanced renal cell carcinoma: Final results. J. Clin. Oncol. 25: 5025.
44. St. Clair, E. W. 2008. The calm after the cytokine storm: lessons from the TGN1412 trial. J. Clin. Invest. 118: 1344-1347.